Literature DB >> 15642445

Clinical outcome and olanzapine plasma levels in acute schizophrenia.

M C Mauri1, C P C Steinhilber, R Marino, E Invernizzi, A Fiorentini, G Cerveri, M L Baldi, F Barale.   

Abstract

PURPOSE: This open label study was performed to evaluate the relationship between the plasma concentration of olanzapine and the response in acute schizophrenic inpatients.
MATERIAL AND METHODS: A total of 54 inpatients, 38 males and 16 females, age ranging from 18 to 75 years, affected by Schizophrenia (DSM IV criteria) during an exacerbation phase were included in the study. Olanzapine (OLZ) was started at a dose of 5-20 mg/day and was increased to a mean dose of 15.27 mg +/-5.53 S.D. Patients were evaluated at baseline, and after 2 weeks, by using BPRS, PANNS, HRS-D, EPSE, and ACS.
RESULTS: BPRS and total PANSS showed a statistically significant improvement at the end of the study. Olanzapine plasma levels (PL) ranged from 5 to 120 ng/ml (mean 33.15 ng/ml +/- 28.28 S.D.) and showed a positive correlation with OLZ dosage. A significant curvilinear correlation between OLZ PL and clinical improvement (BPRS, PANSS and HRS-D percent of amelioration) was observed.
CONCLUSION: Olanzapine plasma level determination seems to be a useful tool in optimizing acute treatment particularly for more problematic cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642445     DOI: 10.1016/j.eurpsy.2004.09.009

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  17 in total

Review 1.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

2.  The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.

Authors:  J A Arnaiz; C Rodrigues-Silva; G Mezquida; S Amoretti; M J Cuesta; D Fraguas; A Lobo; A González-Pinto; M C Díaz-Caneja; I Corripio; E Vieta; I Baeza; A Mané; C García-Rizo; M Bioque; J Saiz; M Bernardo; S Mas
Journal:  Psychopharmacology (Berl)       Date:  2020-11-23       Impact factor: 4.530

3.  Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Authors:  Roza Ghotbi; Buster Mannheimer; Eleni Aklillu; Akira Suda; Leif Bertilsson; Erik Eliasson; Urban Osby
Journal:  Eur J Clin Pharmacol       Date:  2010-02-09       Impact factor: 2.953

Review 4.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

5.  The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine.

Authors:  Tore Haslemo; Helge Refsum; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

6.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 7.  Management of patients presenting with acute psychotic episodes of schizophrenia.

Authors:  Pierre Thomas; Köksal Alptekin; Mihai Gheorghe; Mauro Mauri; José Manuel Olivares; Michael Riedel
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Radioprotective effect of olanzapine as an anti-psychotic drug against genotoxicity and apoptosis induced by ionizing radiation on human lymphocytes.

Authors:  Mohammad Asghari; Zahra Shaghaghi; Soghra Farzipour; Arash Ghasemi; Seyed Jalal Hosseinimehr
Journal:  Mol Biol Rep       Date:  2019-08-12       Impact factor: 2.316

10.  Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Authors:  John K Darby; David J Pasta; Michael G Wilson; John Herbert
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.